Coagulation factor II (F2)
Coagulation factor II, thrombin is a central serine protease in the coagulation cascade and the active enzymatic form of prothrombin (coagulation factor II).
Coagulation factor II, thrombin is a central serine protease in the coagulation cascade and the active enzymatic form of prothrombin (coagulation factor II). It plays a pivotal role in hemostasis by converting fibrinogen to fibrin, promoting clot formation, and amplifying coagulation through activation of other clotting factors and platelets. Because of these functions, thrombin is both a key physiological mediator of blood clotting and an important therapeutic target in thrombosis and anticoagulation research.
Beyond its classical role in coagulation, thrombin is also implicated in inflammatory and fibrotic signaling. Recent biomedical studies have linked thrombin activity to disease processes such as sepsis, pulmonary fibrosis, and broader coagulation abnormalities. Its signaling effects can involve pathways such as PAR-1-mediated responses and interactions with growth factors including TGF-β1 and VEGF, making thrombin relevant not only to thrombosis but also to inflammation, tissue remodeling, and vascular pathology.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
9 papers study coagulation factor ii (f2) directly. Those 9 do not group into themes. Thrombin, protease inhibition, inflammation, thrombosis, and biosensing recur, but the studies address unrelated clinical and chemical questions. No shared direction emerges. They are no more alike than papers drawn from anywhere in the corpus.
Recent Findings on Coagulation factor II (F2)
Recent publications have continued to implicate coagulation factor II (F2, thrombin) in thrombotic, inflammatory, and fibrotic processes. In a network pharmacology and in vivo study of Curcumae Rhizoma for ischemic stroke, F2 was identified as one of the core targets alongside Cyclooxygenase 2 (COX-2), and molecular docking suggested that the compounds alexandrin and hederagenin could bind thrombin with notable affinity 42301551Jun. In a separate multi-omics analysis of bovine serum albumin-induced allergy, F2 was again highlighted within the complement and coagulation cascades pathway, where active metabolites were proposed to act through F10, F2, and PLG 41385805Dec.
Experimental work also directly examined thrombin as a therapeutic target in disease models. In paraquat-induced pulmonary fibrosis, hirudin-mediated thrombin inhibition was investigated as a strategy to blunt fibrosis through the PAR-1–TGF-β1 pathway 41085213Oct. In addition, a review of novel anticoagulant strategies summarized ongoing efforts to target thrombin and other coagulation factors beyond direct oral anticoagulants, emphasizing the continued interest in F2 as a central common-pathway coagulation target 41485707Jan.
Other studies assessed thrombin-related coagulation phenotypes in broader physiological contexts. In middle-aged adults, abdominal fat measures were associated with sex-specific prothrombotic changes, and thrombin generation was evaluated through endogenous thrombin potential and peak thrombin alongside factors VIII, IX, XI, and fibrinogen 42131917May. Together, these publications reinforce the role of F2 in coagulation biology and its relevance to stroke, allergy, fibrosis, and metabolic risk states 42301551Jun41385805Dec41085213Oct42131917May.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-06-15. Last written: 2026-07-29 by GPT. Drafted by language models from published abstracts; not medical advice.